Arrowhead Pharmaceuticals reassured investors it expects Sarepta Therapeutics to uphold its financial commitments under their multi-hundred-million-dollar deal involving RNA therapy programs. Despite Sarepta’s recent operational challenges and stock price declines, Arrowhead indicated no intentions of contract termination have been communicated and outlined contract provisions protecting its interests should Sarepta default. Arrowhead remains on track to earn milestone payments, and analysts believe the company would be well positioned to continue development independently if necessary. The clarification aims to stabilize investor confidence amid ongoing uncertainty surrounding Sarepta.